Research Analysts Issue Forecasts for UBX FY2026 Earnings

Unity Biotechnology, Inc. (NASDAQ:UBX) – Analysts at HC Wainwright decreased their FY2026 EPS estimates for Unity Biotechnology in a research note issued to investors on Monday, March 24th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($0.65) per share for the year, down from their previous forecast of ($0.42). HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Unity Biotechnology’s FY2027 earnings at ($0.09) EPS, FY2028 earnings at $0.25 EPS and FY2029 earnings at $0.40 EPS.

Separately, Chardan Capital lowered their target price on Unity Biotechnology from $6.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday.

Unity Biotechnology Trading Down 5.1 %

Shares of NASDAQ UBX opened at $1.20 on Thursday. The stock has a fifty day moving average price of $1.89 and a 200 day moving average price of $1.51. The company has a market cap of $20.24 million, a P/E ratio of -0.92 and a beta of 1.02. Unity Biotechnology has a 12-month low of $0.94 and a 12-month high of $3.10.

Hedge Funds Weigh In On Unity Biotechnology

An institutional investor recently raised its position in Unity Biotechnology stock. Bridgeway Capital Management LLC lifted its holdings in shares of Unity Biotechnology, Inc. (NASDAQ:UBX) by 100.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 50,000 shares of the company’s stock after acquiring an additional 25,000 shares during the quarter. Bridgeway Capital Management LLC owned 0.30% of Unity Biotechnology worth $49,000 as of its most recent filing with the SEC. 29.49% of the stock is owned by institutional investors and hedge funds.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.